Anika Therapeutics ANIK
NASDAQ ANIK
$20.88 -0.16 (-0.76%)
As of: Sep 9, 2026 · 3:59 PM EDT

Anika Therapeutics (ANIK) Income from Discontinued Operations (2024 - 2025)

Anika Therapeutics' (ANIK) quarterly Income from Discontinued Operations came in at -$1.5 million in Q4 2025, up 92.21% year-over-year from -$785065.7 in Q4 2024, and down 278.37% quarter-over-quarter from $846000.0 in Q3 2025.

Analysis

Anika Therapeutics (ANIK) Income from Discontinued Operations (2024 - 2025) Analysis & Trends

Anika Therapeutics (ANIK) has reported Income from Discontinued Operations for 2 consecutive years, with -$1.5 million the latest figure, recorded in Q4 2025.

  • On a quarterly basis, Income from Discontinued Operations rose 92.21% year-over-year to -$1.5 million in Q4 2025; TTM through Jun 2026 was -$663000.0, a 98.61% increase from a year earlier, with the FY2025 full-year figure at -$901000.0, up 98.11% from the prior year.
  • Income from Discontinued Operations was -$1.5 million for Q4 2025 at Anika Therapeutics, down from $846000.0 in the prior quarter.
  • Over five years, Income from Discontinued Operations peaked at $2.5 million in Q2 2024 and troughed at -$28.1 million in Q3 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Discontinued) (Qtr)
1 Abbott Laboratories 183.04 Bn 177.44 Bn 7.27 Bn -
2 Intuitive Surgical 125.02 Bn 119.81 Bn 1.96 Bn -
3 Medtronic 117.84 Bn 109.02 Bn 6.34 Bn -
4 Stryker 105.50 Bn 102.02 Bn 4.50 Bn -
5 Boston Scientific 66.27 Bn 65.73 Bn 3.85 Bn -
6 Edwards Lifesciences 49.60 Bn 45.35 Bn 1.35 Bn -
7 Alcon 33.70 Bn 32.24 Bn 1.68 Bn -
8 Dexcom 32.06 Bn 30.11 Bn 830.00 Mn -
9 Steris 21.02 Bn 20.54 Bn 684.20 Mn -
10 Anika Therapeutics 277.93 Mn 239.52 Mn 21.24 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 -1.51 Mn
Sep 30, 2025 846,000.00
Jun 30, 2025 677,000.00
Mar 31, 2025 -915,000.00
Dec 31, 2024 -19.38 Mn
Sep 30, 2024 -28.07 Mn
Jun 30, 2024 2.45 Mn
Mar 31, 2024 -2.56 Mn